Well Referenced

Tag: weight gain

Metabolic sequelae of β-blocker therapy: weighing in on the obesity epidemic?

This 2011 study by Lee et al. investigates the metabolic effects of chronic β-blocker therapy. The research comprises a mechanistic study comparing energy expenditure (EE), diet-induced thermogenesis, and habitual activity between β-blocker-treated individuals and matched controls, alongside cross-sectional analyses of body weight, BMI, and waist circumference in patients from diabetes

Read More »
June 26, 2025 No Comments

Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism

This 2011 review by Teff and Kim explores how atypical antipsychotics (AAPs) influence central and peripheral mechanisms regulating appetite and metabolism. AAPs, notably clozapine and olanzapine, are associated with significant weight gain and metabolic disturbances. The authors discuss how these drugs affect hypothalamic pathways, particularly through antagonism of histamine H1

Read More »
June 26, 2025 No Comments

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

This 2021 study conducted a multi-country economic analysis to assess the financial impact of cardiovascular and metabolic adverse events, including weight gain, associated with second-generation antipsychotics (SGAs) in the treatment of schizophrenia. The research highlighted that SGAs, while effective in managing schizophrenia symptoms, are linked to significant metabolic side effects

Read More »
June 26, 2025 No Comments

Antipsychotic-induced weight gain: a comprehensive research synthesis

This 1999 meta-analysis by Allison et al. systematically reviewed the extent of weight gain associated with various antipsychotic medications. The study found that clozapine and olanzapine were associated with the most significant weight gain, with average increases of 4.45 kg and 4.15 kg, respectively, over a 10-week period. Risperidone and

Read More »
June 26, 2025 No Comments

The obesity paradox and weight loss

This 2011 study investigated the relationship between weight changes and mortality in 3,834 men over a mean follow-up of 7 years. Findings revealed that weight loss was associated with higher all-cause mortality, while weight gain correlated with lower mortality compared to stable weight. Specifically, each pound of weight lost per

Read More »
June 26, 2025 No Comments

Bodyweight gain and anticonvulsants: a comparative review

This 2001 review by Jallon and Picard examines the prevalence, mechanisms, and clinical implications of weight gain associated with anticonvulsant therapy. The authors highlight that medications such as valproic acid, carbamazepine, vigabatrin, and gabapentin are frequently linked to significant weight gain in patients with epilepsy, affecting both pediatric and adult

Read More »
June 26, 2025 No Comments

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

This 2011 review highlights the significant metabolic and cardiovascular risks associated with antipsychotic medications, particularly second-generation antipsychotics like clozapine and olanzapine. These drugs are linked to weight gain, hyperglycemia, dyslipidemia, and metabolic syndrome, increasing the risk of type 2 diabetes and cardiovascular disease. The exact mechanisms remain unclear but may

Read More »
June 26, 2025 No Comments

A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-On to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes

This 52-week, multinational, randomized, open-label, non-inferiority trial compared the efficacy and safety of insulin detemir and insulin glargine as add-on therapy to oral glucose-lowering drugs in insulin-naive adults with type 2 diabetes. A total of 582 participants were randomized to receive either insulin detemir or insulin glargine once daily, titrated

Read More »
June 26, 2025 No Comments